Abstract Non-immune neonates and non-immune pregnant women are at risk of developing rubella, measles and mumps infections, including congenital rubella syndrome. We describe the seroepidemiology of measles, mumps and rubella (MMR) in neonates and pregnant women in Catalonia (Spain). Anti-rubella, anti-measles and anti-mumps serum IgG titres were assessed using enzyme-linked immunosorbent assay (ELISA) tests in 353 cord blood samples from neonates of a representative sample of pregnant women obtained in 2013. The prevalence of protective antibody titres in neonates was 96 % for rubella IgG (≥8 IU/ml), 90 % for measles IgG (>300 IU/ml) and 84 % for mumps IgG (>460 EU/ml). Slightly lower prevalences of protective IgG titres, as estimated from the cord blood titres, were found in pregnant women: 95 % for rubella IgG, 89 % for measles IgG and 81 % for mumps IgG. The anti-measles and anti-mumps IgG titres and the prevalences of protective IgG titres against measles and mumps increased significantly (p<0.001) with maternal age. The prevalence of protective anti-measles IgG titres decreased by 7 % [odds ratio (OR)=0.15, p<0.001), the prevalence of protective anti-rubella IgG titres increased by 3 % (OR=1.80, p<0.05) and the MMR vaccination coverage (during childhood) in pregnant women increased by 54 % (OR=2.09, p<0.001) from 2003 to 2013. We recommend to develop an MMR prevention programme in women of childbearing age based on mass MMR vaccination or MMR screening and vaccination of susceptible women to increase immunity levels against MMR.
Introduction
Non-immune neonates and non-immune pregnant women are at risk of developing rubella, measles and mumps infections, including congenital rubella syndrome [1] [2] [3] . In Catalonia and Spain, the current preventive strategy against these diseases is based on the high measles, mumps and rubella (MMR) vaccination coverage during childhood (>90 %) and the intensive epidemiological surveillance activities [4] . Children are vaccinated with two doses of MMR vaccine, given at 15 months and 4 years of age [4] . Rubella vaccination of girls aged 11 years began in 1978, and MMR vaccination of children at 12 months began in 1980. In 1988, a second dose of MMR vaccine was added at 11 years of age for all children to replace the rubella vaccine administered to girls. In 1998, administration of the second dose of MMR vaccine was shifted to 4 years of age to ensure that more than 95 % of children <10 years of age were immune to measles [4] .
In 2010, the European Region of the World Health Organization renewed their commitment to the elimination of measles and rubella and the prevention of congenital rubella by the year 2015, and reduction of mumps incidence [5] [6] [7] . Since 1985, great efforts have been made in Catalonia, Spain and other European countries to eliminate measles and rubella and reduce mumps incidence, but cases and outbreaks of MMR are still occurring [8] [9] . In 2013, 36,321 cases of measles, 28, 813 cases of mumps and 964 cases of rubella were reported in Europe [9] . Indigenous measles virus transmission was interrupted in Catalonia in 2000, as well as in nine other regions of Spain in 2005 [10] , but measles re-emerged in Catalonia in 2006 and 132 cases were reported in Spain in 2013 [9, 10] . Several reasons could explain the persistence of MMR in Catalonia, Spain and other European countries, including the failure to complete MMR vaccination in some areas or population groups [11, 12] ; the mobility of people carrying measles, rubella and mumps infections; and the lack of necessary prevalence of protected individuals (91 %) required to block the transmission of MMR viruses in the community [4, 13] .
A seroepidemiological study carried out in Catalonia in 2003 assessed immunity levels against measles and rubella in neonates (cord blood samples), obtaining a prevalence of protective IgG titres of 98 % for measles [14] and 93 % for rubella [15] . The objectives of this study were: (1) to assess anti-rubella, anti-measles and anti-mumps IgG titres in neonates (cord blood samples) in 2013; (2) to assess the prevalence of protective anti-rubella, anti-measles and anti-mumps IgG titres in neonates and pregnant women; (3) to identify population groups with higher priority for preventive and epidemiological surveillance activities; and (4) to compare the prevalence of protective anti-measles and anti-rubella IgG titres in neonates and the MMR vaccination coverage in pregnant women in 2003 and 2013.
Methods

Sample selection
The serological study was carried out in cord blood samples of neonates from a representative sample of pregnant women obtained in Catalonia in 2013. Sampling was carried out in two stages. In the first stage, hospitals were selected. In the second stage, pregnant women who were attended for delivery between January and April of 2013 were asked to participate in the study. All pregnant women were eligible for the study, except those meeting any of the following exclusion criteria: administration of immunosuppressants or other immunomodifying drugs within the 6 months preceding childbirth, severe concomitant diseases (neoplasia, kidney or liver disease, immunosuppression, malabsorption syndrome), family history of immunodeficiency and administration of immunoglobulins or any blood product within the 6 months preceding childbirth. The sample size, calculated taking into account an alpha error of 5 %, a prevalence of 50 %, a precision of 6.2 % and a design effect of 1.5, was 375. In each hospital, selected pregnant women were informed of the objectives of the study and asked to participate. The Research Ethics Board (REB) of the Vall d'Hebron hospital, Josep Trueta hospital and Mar hospital reviewed and approved the objectives and methodology of the study. Written informed consent was obtained from all participants to participate in the study, obtain umbilical cord blood samples, collect socio-demographic information and assess anti-rubella, anti-measles and anti-mumps IgG titres.
Questionnaire
All participants completed a questionnaire to collect sociodemographic and vaccination information. The sociodemographic variables included: age, place of birth, place of residence, education and social class. The place of residence was classified into urban (>10,000 inhabitants) and rural (<10, 000 inhabitants) habitats. The variable immigration was defined according to the place of birth. Immigrants were considered as women who had not been born in Catalonia or another region of Spain. The educational level was classified into lower than primary education and primary or higher education. The socio-economic level was determined by the occupation, classifying all participants into three socio-economic groups (I-III, IV-V and VI), according to the English classification [16] . The MMR and rubella monovalent vaccination information was used to assess the vaccination coverage. The MMR vaccination was considered correct in pregnant women when they had received two doses of MMR vaccine at 12-15 months and 4 years of age, or one dose of MMR vaccine in those aged ≥35 years (vaccinated before 1988).
Serological analysis
Blood samples were obtained from the umbilical cord at childbirth. Immunoglobulin G (IgG) titres against rubella, measles and mumps were measured using enzyme-linked immunosorbent assays (ELISA; Siemens Healthcare Diagnostics, Germany), according to the manufacturer's instructions. The lowest levels of detection were 4 IU/ml for anti-rubella IgG, 150 IU/ ml for anti-measles IgG and 230 EU/ml for anti-mumps IgG. In this study, serum samples with anti-rubella IgG ≥8 IU/ml, anti-measles IgG >300 IU/ml and anti-mumps IgG >460 EU/ ml were considered positive, and serum samples with antirubella IgG <8 IU/ml, anti-measles IgG ≤300 IU/ml and anti-mumps IgG ≤460 EU/ml were considered negative [17, 18] . Serum samples with equivocal serologic results for rubella (4−8 IU/ml), measles (150−300 IU/ml) and mumps (230−460 EU/ml) were retested, considering them as negative when, in the second assessment, titres were <8 IU/ml for rubella IgG, ≤300 IU/ml for measles IgG and ≤460 EU/ml for mumps IgG. Neonates with titres ≥8 IU/ml for rubella IgG, >300 IU/ml for measles IgG and >460 EU/ml for mumps IgG were considered to be protected [17] .
The prevalence of protective anti-rubella, anti-measles and anti-mumps IgG titres in pregnant women was determined from IgG titres in cord blood samples by taking into account the following cord:maternal ratios (titre in cord blood:titre in pregnant women): 1:0.83 for rubella antibodies [19] , 1:0.89 for measles antibodies [19] [20] [21] and 1:0.77 for mumps antibodies [19] . The cord:maternal ratio for measles IgG antibodies in pregnant women assumed in this study was the average ratio obtained from three seroprevalence studies conducted in developed countries [19] [20] [21] .
Statistical analysis
Statistical analysis of the results was carried out using IBM SPSS version 18 software (IBM SPSS, Chicago, IL, USA). Geometric mean anti-rubella, anti-measles and anti-mumps IgG titres in neonates and the prevalence of protective antirubella, anti-measles and anti-mumps IgG titres in neonates and pregnant women were determined in different sociodemographic groups. Ninety-five percent confidence intervals (CIs) were calculated for means and prevalences using the parametric method and the exact binomial method, respectively. The t-test was used to compare mean IgG titres, considering a p<0.05 as being statistically significant. Correlation between anti-rubella, anti-measles and anti-mumps IgG titres and study variables were assessed using Person's correlation coefficient, considering a p<0.05 as being statistically significant. Multiple linear regression equations to explain anti-rubella, anti-measles and anti-mumps log IgG titres were developed including all study variables (age, habitat of residence, immigration, social class and educational level) in the models. The Chi-square test and odds ratio (OR) were used to compare prevalences and percentages of vaccination coverage in different socio-demographic groups, considering a p<0.05 as being statistically significant. Multiple logistic regression analysis was used to adjust significant ORs obtained in the univariate analysis, including all study variables in the models.
The prevalences of protective anti-measles and anti-rubella IgG titres found in neonates were compared to the prevalences found in the seroprevalence study conducted in 2003 [14, 15] , considering the same cut-off levels for positivity: >300 IU/ml for measles IgG and ≥8 IU/ml for rubella IgG. The MMR vaccination coverage in pregnant women during childhood (two doses in pregnant women aged <35 years and one dose in those aged ≥35 years) obtained in this study was compared to the vaccination coverage for one dose of MMR vaccine obtained in the study conducted in 2003. The Chi-square test and OR were used to compare prevalences of protective antibody titres and percentages of vaccination coverage in 2013 and 2003, considering a p<0.05 as being statistically significant. The age-standardised prevalences in 2003 and 2013 were calculated using the Catalan population (pregnant women) in 2012 [22] as the standard population. Thus, the prevalences in 2003 and 2013 were obtained by weighting the proportion for different age groups, taking into account the distribution of the Catalan population.
Results
The total number of umbilical cord blood samples included in the study was 353 (94 % participation rate). The distribution of the sample of pregnant women, according to sociodemographic variables, was similar to the distribution in the population of pregnant Catalan women [22] , although pregnant women 14-24 years old and those living in urban locations were over-represented in the sample. Table 1 presents the geometric mean titres (GMT) and the prevalence of protective IgG titres in neonates for rubella, measles and mumps antibodies. The GMT was 5.3 IU/ml for anti-rubella IgG, 25.3 IU/ml for anti-measles IgG and 28.9 EU/ml for anti-mumps IgG. Anti-rubella, anti-measles and anti-mumps titres in neonates increased with maternal age, with significant correlation coefficients of 0.247 (p=0.001) for anti-measles IgG and 0.16 (p=0.002) for anti-mumps IgGs. Three simple linear regression equations were used to explain anti-measles, anti-mumps and anti-rubella IgG titres in neonates, depending on maternal age: log anti-measles IgG (IU/ ml)=2.247+0.026 age, log anti-mumps IgG (EU/ml)=2.697+ 0.016 age and log anti-rubella IgG (IU/ml)=1.493+0.006 age. Multiple linear regression analysis showed that anti-measles and anti-mumps IgG titres in neonates were associated with maternal age independently of other maternal sociodemographic variables, with a p<0.001 for measles IgG antibodies and a p<0.005 for mumps IgG antibodies.
The prevalence of protective IgG titres in neonates was 96.3 % for rubella, 90.4 % for measles and 84.1 % for mumps ( Table 1 ). The prevalence of anti-measles and anti-mumps protective IgG titres increased significantly (p<0.001) with maternal age. Multiple logistic regression analysis showed that the prevalence of anti-measles and anti-mumps protective IgG titres were associated (p<0.001) with maternal age independently of the other studied maternal socio-demographic variables. In all, 274 neonates (77.6 %) had protective IgG titres against rubella, measles and mumps, 58 (16.4 %) had protective titres against two diseases, 18 (5.1 %) had protective titres against one disease and three neonates (0.8 %) were unprotected against rubella, measles and mumps. Table 2 presents the prevalence of pregnant women with protective IgG titres against rubella, measles and mumps. The overall prevalence of protected women was 95.5 % for rubella, 88.7 % for measles and 81 % for mumps. In all, 257 women (72.8 %) had protective IgG titres against rubella, measles and mumps, 72 (20.4 %) had protective titres against two diseases, 21 (5.9 %) had protective titres against one disease and three women (0.8 %) were unprotected against rubella, measles and mumps. The prevalence of protective IgG titres against rubella, measles and mumps was slightly lower than in neonates, but the differences were not statistically significant. The prevalence of protective IgG titres against measles and mumps increased significantly (p<0.001) with maternal age. Three simple linear regression equations were used to explain antibody IgG titres in pregnant women, depending on age: log anti-measles IgG (IU/ml)=2.396+0.026 age, log anti-mumps IgG (EU/ml)=2.584+0.016 age and log anti-rubella IgG (IU/ ml)=1.412+0.006 age. Multiple linear regression analysis showed that maternal age was associated with anti-measles IgG and anti-mumps IgG in pregnant women independently of the other studied socio-demographic variables. Table 3 presents MMR and rubella vaccination coverage in pregnant women (during childhood) and shows that 51 % of women were vaccinated with the MMR vaccine and 12 % with the rubella vaccine. Overall, 62 % of the women had been vaccinated with the MMR vaccine or the rubella vaccine. MMR vaccination coverage increased with age (p<0.001), while rubella vaccination coverage decreased with age (p<0.001). The percentages of vaccination coverage were higher in autochthonous than immigrant women, with ORs of 1.37 for MMR vaccination, 4.67 for rubella vaccination, and 2.12 (95 % CI: 1.29-3.49, p<0.01) for the MMR or rubella vaccines. (Table 3) . Table 4 a Protective IgG titres in pregnant women: ≥8 IU/ml for anti-rubella IgG, >300 IU/ml for anti-measles IgG and >460 for anti-mumps IgG. IgG titres in pregnant women were estimated from titres in cord blood samples by assuming that titres in pregnant women were 17, 11 and 23 % lower than in cord blood samples b Analysis for pregnant women aged <30 years. MMR vaccination (obtained by questionnaire) was considered correct when women had received two doses of MMR vaccine at 12-15 months and 4 years of age 
Discussion
The prevalence of protective antibody titres higher than 95 % for rubella and lower than 91 % for measles and mumps in neonates and pregnant women shows that, in 2013, neonates and pregnant women were adequately protected against rubella but not against measles and mumps in Catalonia. Consequently, a new preventive strategy should be developed to reduce the risk of measles and mumps infections in neonates and pregnant women. The prevalence of protective antibody titres against rubella in neonates and pregnant women was higher than the prevalence of protective antibody titres against measles and mumps. This result could be explained by the higher vaccine-induced immunity provided by MMR vaccines against rubella than against measles and mumps [17, 23] , and by previous programmes of rubella monovalent vaccinations in Catalonia. Davidkin et al. [23] found that individuals vaccinated with two doses of MMR vaccine in Finland between 1982 and 1989 had a prevalence of protective IgG titres of 100 % for rubella antibodies, 95 % for measles antibodies and 74 % for mumps antibodies.
The GMT and the prevalence of protective anti-measles IgG titres was higher in the neonates of women aged ≥35 years than in those of women aged <35 years, as well as being higher in women aged ≥35 years than in women aged <35 years. Since immunity to measles had been acquired through measles vaccinations in women aged <35 years but by natural infection in women aged ≥35 years, these results can be explained by the increased immunity against measles viruses in naturally immune women than in vaccinated women [21, [24] [25] [26] [27] . Leuridan et al. [24] found, in the United Kingdom in 2008, that vaccinated women had significantly lower IgG titres than naturally immune women (779 mIU/ml vs. 2, 687 mIU/ml, p<0.001) and that the neonates of vaccinated women also had significantly lower IgG titres than the neonates of naturally immune women (698 mIU/ml vs. 2,221 mIU/ml, p<0.001).
Univariate and multivariate linear regression analysis carried out in this study showed a positive correlation between the anti-measles and anti-mumps IgG titres in neonates and pregnant women and maternal age. On the other hand, the study showed a null correlation between anti-rubella IgG titres and maternal age. Seroprevalence studies carried out in other countries found positive correlations between the anti-measles IgG titres in neonates/pregnant women and maternal age [14, [28] [29] [30] , and positive [28] , negative [31] [32] [33] [34] [35] or null [36, 37] correlations between the anti-rubella IgG titres in neonates/ pregnant women and maternal age. The present study found the prevalence of protective antirubella IgG titres to be similar in the neonates of autochthonous and immigrant women (96.9 vs. 95.2 %). However, in the study carried out in 2003, the prevalence was higher in the neonates of autochthonous women than in those of immigrant women (94.6 vs. 89.0 %, p<0.001) [15] . This change can be explained by the higher MMR vaccination rate in immigrant women in 2013 than in 2003.
This study shows that the susceptibility to measles among neonates increased by 7 % from 2003 to 2013. This result can be explained by three factors: (1) greater proportion of neonates of vaccinated women in 2013 than in 2003; (2) waning vaccine-induced immunity for measles antibodies; and (3) lower circulation of wild measles viruses after 1980. Several studies have shown that neonates of vaccinated women have lower protective immunity levels against measles than neonates of naturally infected women [21, [24] [25] [26] [27] , and that vaccine-induced measles antibodies wane with time [23] . Consequently, the higher proportion of neonates of vaccinated women and the lower proportion of naturally immunised women in 2013 than in 2003 has generated a lower prevalence of neonates protected against measles in 2013 than in 2003. Our study also shows that the susceptibility to rubella among neonates decreased by 3 % from 2003 to 2013. This result indicates that the MMR vaccination programme, developed since 1980, has been able to maintain high anti-rubella immunity levels in pregnant women and neonates since 2003. A possible reason for this is that the MMR vaccine generates high immunity levels against rubella [23] , which could be similar to those generated by rubella infections. Davidkin et al. [23] found a prevalence of positive results of 93 % for anti-rubella IgG 15 years after the MMR vaccination (two doses), while the prevalence of positive results was 82 % for anti-measles IgG and 40 % for anti-mumps IgG.
The overall MMR and rubella vaccination rates found in this study in pregnant women were 51 and 12 %, respectively. The MMR vaccination rate increased by 54 % from 2003 to 2013 due to higher MMR vaccination rates in both autochthonous and immigrant women in 2013. However, the lower MMR vaccination rate found in 2013 in immigrant women compared autochthonous women suggests that the MMR vaccination status should be reviewed in all immigrant women.
The prevalences of anti-rubella, anti-measles and antimumps protective IgG titres in neonates and pregnant women found in this study were similar to and different from the prevalences found in seroprevalence studies carried out in other countries after 2000. However, it is difficult to compare prevalences obtained in different seroprevalence studies due to differences in sampling methods, populations studied and serological tests used. The prevalence of protective antirubella IgG titres found in this study in pregnant women (95 %) was similar to the prevalence found in pregnant women in the United States of America (98 %) [37] , Colombia (93 %) [33] , Brazil (92 %) [34] , Iran (96 %) [30] , Turkey (94-100 %) [36, 39] and Australia (93 %) [31] , while it was higher than the prevalence found in Taiwan (89 %) [40] , Germany (87 %) [41] , Sudan (72 %) [42] and Poland (89 %) [35] . The prevalence of protective anti-measles titres found in this study in pregnant women (89 %) was similar to the prevalence found in pregnant women or neonates in the United States of America (88 %) [37] , Argentina (87 %) [28] , Japan (80-90 %) [29] and China (90 %) [43] , while it was higher than the prevalence found in Germany (79 %) [41] and Iran (82 %) [30] . The prevalence of protective anti-mumps titres found in this study in pregnant women (81 %) was similar to the prevalence found in the United States of America (84 %) [44] .
The prevalence of protective anti-rubella IgG titres found in this study in neonates (96 %) was higher than the prevalence found in neonates in Switzerland (91 %) [45] and the United Kingdom (92 %) [46] . The prevalence of protective anti-measles IgG titres found in this study in neonates (90 %) was similar to the prevalence found in neonates in Switzerland (91 %) [45] and it was higher than the prevalence found in the United Kingdom (80 %) [24] , the Netherlands (83 %) [46] and Israel (50-81 %) [21, 24] . The prevalence of protective antimumps IgG titres found in this study in neonates (84 %) was similar to the prevalence found in neonates in the Netherlands (83 %) [46] and it was higher than the prevalence found in Switzerland (62 %) [45] .
This study has several limitations. First, neonates and pregnant women who had anti-rubella, anti-measles and antimumps titres ≥8 IU/ml, >300 IU/ml and >460 EU/ml, respectively, were considered to be protected against these diseases. Although using lower cut-off titres should result in higher prevalences of protective titres, these cut-off points are the most accurate ones for deciding immune protection against rubella, measles and mumps [10, 17] . Second, the prevalences of protective IgG titres in pregnant women were determined by assuming cord:maternal ratios of 1:0.83, 1:0.89 and 1:0.77 for rubella, measles and mumps antibody titres, respectively. Lower cord:maternal ratios would result in lower prevalences of protective IgG titres in pregnant women. However, the cord:maternal ratios assumed in this study can be considered adequate for estimating the prevalence of protective IgG titres in pregnant women for two reasons: seroprevalence studies have found strong correlations between IgG titres in cord blood samples and pregnant women [23] [24] [25] [26] and the transplacental transport of antibodies is much lower in neonates of women with high antibody titres [21, 38] . Third, the MMR and rubella vaccination rates that were obtained for pregnant in 2013 could be lower than the actual vaccination rate because of recall bias. However, alternative vaccination information was not available for the sample of pregnant women that was studied. Fourth, the MMR vaccination rate in pregnant women in 2013 was compared to the measles vaccination rate in 2003.
This study shows that the current preventive strategy against measles, rubella and mumps, which is based on high MMR vaccination coverage during childhood, can be considered adequate for preventing rubella and congenital rubella infections. However, this strategy is not effective enough in achieving and maintaining high anti-measles and anti-mumps immunity levels in neonates and pregnant women, and the risk of measles and mumps infections could be higher in the future because of the decline in the MMR vaccine-induced antibody levels [23, 25, 47, 48] . Neonates and pregnant women are vulnerable to measles and mumps infections for the following reasons: (1) the neonates lose their measles and mumps antibodies before receiving the first dose of the MMR vaccine [19, 43] ; (2) the prevalence of protective anti-measles and antimumps IgG titres found in this study was lower than the critical prevalence necessary to block the transmission of measles and mumps viruses in the community (91 %) [4] ; (3) measles and mumps can be transmitted from imported cases to susceptible neonates and pregnant women [2, 3, 12, 17] ; (4) measlesrelated complications are frequent in neonates [2] .
Therefore, it is necessary to develop new preventive strategies to increase immunity levels against measles and mumps in pregnant women and neonates, including: (1) MMR screening and vaccination of susceptible women of childbearing age; (2) MMR vaccination (catch-up) of women of childbearing age who have no documentation of completed vaccination, unless they have laboratory evidence of immunity to MMR or documentation of provider-diagnosed MMR; and (3) promotion of MMR vaccination during childhood. Women aged <35 years and immigrant women should be the priority groups for these preventive programmes. The mass MMR vaccination strategy is the most cost-effective immunisation strategy, since screening costs are higher than vaccination costs [49] . However, MMR screening and vaccination will be the preferred option for women of childbearing age who are willing to avoid MMR vaccination. The preventive strategy based on immunising women of childbearing age has been used successfully to reduce the incidence of pertussis in pregnant women and neonates in the United Kingdom [50] . Periodic seroprevalence studies should be carried out in Catalonia, as well as in other regions and countries of Europe, to assess the impact of MMR vaccination programmes and to identify the population groups that should have higher priority for preventive and epidemiological surveillance activities [4] .
In conclusion, susceptibility to measles increased and susceptibility to rubella decreased from 2003 to 2013. We recommend to develop an MMR prevention programme in women of childbearing age based on mass MMR vaccination or MMR screening and vaccination of susceptible women to increase immunity levels against MMR.
